| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 217.41 Million |
| Market Size (2030) | USD 284.69 Million |
| CAGR (2025 - 2030) | 5.54 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Infantile Spasms Therapeutics Market Analysis
The Infantile Spasms Therapeutics Market size is estimated at USD 217.41 million in 2025, and is expected to reach USD 284.69 million by 2030, at a CAGR of 5.54% during the forecast period (2025-2030).
The growth of the infantile spasms market is influenced by several key factors that underscore its dynamics and evolution, including the rising burden of infantile spasm cases and technological advancements in developing new therapeutics for this disease. Various factors lead to infantile spasms, including infections, brain injury, or arteriovenous malformations. Hence, the growing risk of these factors increases the prevalence of infantile spasms, which will boost the market growth during the forecast period.
For instance, according to the World Health Organization (WHO), in June 2024, quick and adequate identification and treatment of infections in young infants (0-59 days old), especially newborns (0-28 days old), are crucial to ensure their survival and reduce morbidity. In addition, the same source stated that neonatal sepsis significantly contributes to the health challenges faced by low- and middle-income countries like India and African countries. This shows the significantly high burden of neonatal infections among various countries, which can lead to infantile spasms, thereby increasing the usage of therapeutics and boosting market growth during the study period.
Also, the growing awareness through campaigns on infantile spasm disease and its management is expected to propel the market growth over the coming years. For instance, in November 2023, the President of TSC Alliance emphasized that the primary objective of Infantile Spasms Awareness Week (ISAW), observed from December 1 to 7, is to heighten awareness and comprehension of infantile spasms. This is achieved by disseminating educational resources to healthcare providers, caregivers, and the general public. This campaign also prioritizes infantile spasm treatment due to its health emergency. Hence, the awareness campaigns likely drive the market growth during the forecast period.
Therefore, the significant burden of infantile spasms due to various factors and growing awareness of the treatment are expected to drive the market growth during the forecast period. However, the low success rate of treatment and increased risk of side effects and adverse drug effects are expected to hinder the market's growth during the forecast period.
Infantile Spasms Therapeutics Market Trends
Vigabatrin is Expected to Hold a Significant Share in the Market During the Forecast Period
Vigabatrin is a medication primarily used to treat infantile spasms. Its growth in the infantile spasms therapeutics market is expected to hold a significant share owing to its high effectiveness in controlling the symptoms, increasing new product approvals and launches in various countries, and continued research and developments. In addition, the growing burden of infantile spasms due to infections and brain injury in infants is expected to increase the usage of vigabatrin for infantile spasms management, thereby boosting segment growth during the study period.
As per the new guidelines, vigabatrin is crucial in managing infantile spasms. This will likely increase the usage of these products and is expected to boost segment growth during the forecast period. For instance, in May 2024, the American Academy of Neurology developed a new guideline to evaluate the treatment of infantile spasms. According to these guidelines, vigabatrin shows promise in short-term infantile spasm treatment and holds potential for children with tuberous sclerosis. The guideline concluded that there isn't enough evidence to support recommending alternative treatments for infantile spasms. Therefore, the usage of vigabatrin is expected to increase and likely surge the market growth during the forecast period.
Also, the growing number of vigabatrin product approvals and launches increases the product's availability, which is expected to drive market growth during the study period. For instance, in July 2023, Upsher-Smith Laboratories LLC launched VIGADRONE (vigabatrin) tablets, USP 500 mg, as a fully substitutable, AB-rated generic alternative to Sabril (vigabatrin) tablets, 500 mg, in the United States. Similarly, in March 2023, Zydus Lifesciences Limited received approval from the United States Food and Drug Administration (USFDA) for Vigabatrin oral solution USP, 500 mg.
Therefore, the new guidelines and growing product approvals and launches are expected to boost the segment growth during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America Dominates the Global Infantile Spasms Therapeutics Market During the Forecast Period
The growth of the infantile spasms therapeutics market in North America can be attributed to several key factors, such as increasing awareness of infantile spams, advancements in medical research, the high burden of infantile spasms, and growing product approvals and launches.
The high burden of infantile spam cases in the region is expected to increase the usage of its therapeutic products, which is expected to boost the market growth during the study period. For instance, according to the data published by the American Academy of Pediatrics in December 2023, each year, over 1,200 infants in the United States are affected by infantile spasms. Although uncommon, these seizures pose a significant risk, potentially leading to lasting damage to a developing infant's brain. Hence, this condition is termed an emergency and increases the need for therapeutics, thereby boosting the market growth in the region.
Also, the approvals for new products in the region increase the availability of the products, which is likely to drive market growth. For instance, in March 2022, Lupin Limited (Lupin) received approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatrin for oral solution USP, 500 mg.
In addition, the government initiatives to manage the drug shortage are expected to boost the market growth. For instance, in November 2023, Health Canada authorized the importation of vigabatrin sachets approved by foreign authorities to mitigate the effects of a shortage. Therefore, the high burden of infantile spam cases, new product approvals, and government initiatives are expected to raise the demand for infantile spam therapeutics, boosting the market growth in the region.
Get Analysis on Important Geographic Markets
Download PDF
Infantile Spasms Therapeutics Industry Overview
The infantile spasms therapeutics market is fragmented and has several market players. These companies engage in various strategic activities, such as product launches and agreements, which likely increase the availability of products in various countries. Companies like Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, H. Lundbeck, Insys Therapeutics, Mallinckrodt, Orphelia Pharma, and Retrophin hold a substantial market share.
Infantile Spasms Therapeutics Market Leaders
-
Mallinckrodt
-
H. Lundbeck
-
Insys Therapeutics
-
Orphelia Pharma
-
Catalyst Pharmaceuticals
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Infantile Spasms Therapeutics Market News
- April 2024: Pyros Pharmaceuticals Inc. launched its VIGPODER (vigabatrin) oral solution in the United States. It is indicated as a monotherapy for the treatment of infantile spasms in infants aged one month to two years.
- March 2024: Mallinckrodt PLC received approval from the Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the Acthar Gel (repository corticotropin injection) single-dose pre-filled SelfJect Injector, a new delivery device for Acthar Gel. As monotherapy, it is used for the treatment of infantile spasms in infants and children under two years of age.
Infantile Spasms Therapeutics Industry Segmentation
As per the scope of the report, infantile spasms, also called West syndrome, is a rare type of epilepsy that typically begins in infancy, usually between 3 and 8 months of age. It is characterized by sudden, jerking movements or spasms of the body, often in clusters. Medications that aim to suppress infantile spasms are considered under infantile spasms therapeutics.
The infantile spasms therapeutics market is segmented into drug type, route of administration, distribution channel, and geography. By drug category, the market is segmented into adrenocorticotropic hormone (ACTH), corticosteroids, and antiepileptic drugs. The antiepileptic drugs include vigabatrin and other antiepileptic drugs. By route of administration, the market is segmented into oral and parenteral. By distribution channels, the market is segmented into offline pharmacies and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market sizing and forecasts are based on the value (USD) for each segment.
| By Drug Category | Adrenocorticotropic Hormone (ACTH) | ||
| Corticosteroids | |||
| Antiepileptic Drugs | Vigabatrin | ||
| Other Antiepileptic Drugs | |||
| By Route of Administration | Oral | ||
| Parenteral | |||
| By Distribution Channels | Offline Pharmacies | ||
| Online Pharmacies | |||
| Geography | North America | ||
| Europe | |||
| Asia-Pacific | |||
| Middle East and Africa | |||
| South America | |||
Need A Different Region or Segment?
Customize Now
Infantile Spasms Therapeutics Market Research FAQs
How big is the Infantile Spasms Therapeutics Market?
The Infantile Spasms Therapeutics Market size is expected to reach USD 217.41 million in 2025 and grow at a CAGR of 5.54% to reach USD 284.69 million by 2030.
What is the current Infantile Spasms Therapeutics Market size?
In 2025, the Infantile Spasms Therapeutics Market size is expected to reach USD 217.41 million.
Who are the key players in Infantile Spasms Therapeutics Market?
Mallinckrodt, H. Lundbeck, Insys Therapeutics, Orphelia Pharma and Catalyst Pharmaceuticals are the major companies operating in the Infantile Spasms Therapeutics Market.
Which is the fastest growing region in Infantile Spasms Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Infantile Spasms Therapeutics Market?
In 2025, the North America accounts for the largest market share in Infantile Spasms Therapeutics Market.
What years does this Infantile Spasms Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Infantile Spasms Therapeutics Market size was estimated at USD 205.37 million. The report covers the Infantile Spasms Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Infantile Spasms Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Infantile Spasms Therapeutics Industry Report
Statistics for the 2025 Infantile Spasms Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Infantile Spasms Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
